Matches in Wikidata for { <http://www.wikidata.org/entity/Q73893853> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q73893853 description "article scientifique publié en 1997" @default.
- Q73893853 description "artículu científicu espublizáu en xunu de 1997" @default.
- Q73893853 description "im Juni 1997 veröffentlichter wissenschaftlicher Artikel" @default.
- Q73893853 description "scientific article published on 01 June 1997" @default.
- Q73893853 description "wetenschappelijk artikel" @default.
- Q73893853 description "наукова стаття, опублікована в червні 1997" @default.
- Q73893853 name "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA" @default.
- Q73893853 name "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment" @default.
- Q73893853 type Item @default.
- Q73893853 label "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA" @default.
- Q73893853 label "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment" @default.
- Q73893853 prefLabel "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA" @default.
- Q73893853 prefLabel "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment" @default.
- Q73893853 P1433 Q73893853-CF79B1AC-7EFC-44FE-B6DC-6F165F7B6F06 @default.
- Q73893853 P1476 Q73893853-99ADF43F-74BE-4EDE-8357-A0DC7C7574D8 @default.
- Q73893853 P2093 Q73893853-1FC1B5E5-6001-4B15-9CEF-55E873662B2B @default.
- Q73893853 P2093 Q73893853-230EA7AB-FD26-4C60-A874-27068E1CE1AB @default.
- Q73893853 P2093 Q73893853-3613C143-3444-4695-A3D6-667A2A7F1ED5 @default.
- Q73893853 P2093 Q73893853-6C6709C6-671A-412E-A2D2-A802FE88F99C @default.
- Q73893853 P2093 Q73893853-711C23F5-2F48-4A52-ADF6-B4AF11F95A4B @default.
- Q73893853 P2093 Q73893853-C06813C1-C61D-46C9-BB6B-26B2192F16A5 @default.
- Q73893853 P2093 Q73893853-EFC70EA8-F6F8-49C1-88F4-0EBAEC3A6FE4 @default.
- Q73893853 P2093 Q73893853-F2225C7D-2C32-4BB4-B428-76972764CE44 @default.
- Q73893853 P2860 Q73893853-156A0587-CD45-47EE-889B-142AEB2888EC @default.
- Q73893853 P2860 Q73893853-2745591C-3406-4B4E-AA70-80D6304E450F @default.
- Q73893853 P2860 Q73893853-30B90811-829F-4BBA-BF2A-79100359EA85 @default.
- Q73893853 P2860 Q73893853-3F688F94-AC1B-4967-93AB-FFA41DD2D582 @default.
- Q73893853 P2860 Q73893853-605AA219-4A7B-43DF-A0B0-830FFF8F73D1 @default.
- Q73893853 P2860 Q73893853-805A88F2-4AB3-4545-AC6F-FFEB17B39AAD @default.
- Q73893853 P2860 Q73893853-B5EACFB3-ABE9-4973-9761-BE3EE549BE6B @default.
- Q73893853 P304 Q73893853-614E2AEB-EA6B-4BC7-80E9-E3D5878987BE @default.
- Q73893853 P31 Q73893853-192E0F85-2588-497A-8911-82B30616BFFF @default.
- Q73893853 P356 Q73893853-CFB94E4A-A38F-4CE1-A50B-A8216FD9F491 @default.
- Q73893853 P433 Q73893853-E3A63AE5-08BB-46B1-BBB9-48437FA1A377 @default.
- Q73893853 P478 Q73893853-208356EB-7FD4-4223-9535-CDA841C322DF @default.
- Q73893853 P50 Q73893853-DC5ECC4A-0630-4779-8A4F-D991F0505C75 @default.
- Q73893853 P577 Q73893853-1A3E3110-5BBB-4BA4-A94B-CBD594FFF4A0 @default.
- Q73893853 P698 Q73893853-FF0BBFA7-9AD8-4B12-ACEB-B55B3F447DFA @default.
- Q73893853 P921 Q73893853-2085B02C-1230-4F24-828C-5AF00BBD9BAC @default.
- Q73893853 P921 Q73893853-7511A9CC-0AC1-456B-B590-BBFF85767785 @default.
- Q73893853 P921 Q73893853-ABC17876-52AE-4493-B2F1-354C1179710F @default.
- Q73893853 P356 S0959-8049(97)00105-6 @default.
- Q73893853 P698 9376181 @default.
- Q73893853 P1433 Q332260 @default.
- Q73893853 P1476 "Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)" @default.
- Q73893853 P2093 "A Goldhirsch" @default.
- Q73893853 P2093 "B Thürlimann" @default.
- Q73893853 P2093 "H Bonnefoi" @default.
- Q73893853 P2093 "M Castiglione" @default.
- Q73893853 P2093 "M F Fey" @default.
- Q73893853 P2093 "R Morant" @default.
- Q73893853 P2093 "S F Hsu-Schmitz" @default.
- Q73893853 P2093 "T Löhnert" @default.
- Q73893853 P2860 Q24564911 @default.
- Q73893853 P2860 Q59289640 @default.
- Q73893853 P2860 Q71611886 @default.
- Q73893853 P2860 Q71611889 @default.
- Q73893853 P2860 Q72082638 @default.
- Q73893853 P2860 Q72705449 @default.
- Q73893853 P2860 Q72736724 @default.
- Q73893853 P304 "1017-1024" @default.
- Q73893853 P31 Q13442814 @default.
- Q73893853 P356 "10.1016/S0959-8049(97)00105-6" @default.
- Q73893853 P433 "7" @default.
- Q73893853 P478 "33" @default.
- Q73893853 P50 Q120654 @default.
- Q73893853 P577 "1997-06-01T00:00:00Z" @default.
- Q73893853 P698 "9376181" @default.
- Q73893853 P921 Q410513 @default.
- Q73893853 P921 Q412178 @default.
- Q73893853 P921 Q42824827 @default.